Our research expertise spans cancer genomics, DNA damage, RNA biology, and drug development. We are also expanding our focus on drug delivery, particularly through nanotechnology-based methods for delivering small RNA mimics and inhibitors.
News
- Nature Communications: Loss of CD98HC phosphorylation by ATM impairs antiporter trafficking and drives glutamate toxicity in Ataxia telangiectasia (Bishop Lab)
- BioMolecular NMR Assignments: The 1H, 15N and 13C backbone resonance assignments of the N-terminal (1-149) domain of Serpine mRNA Binding Protein 1 (SERBP1) (Libich Lab)
- Science: CTC1-STN1-TEN1 controls DNA break repair pathway choice via DNA end resection blockade (Sung & Libich Labs)
- PNAS: Phase separation of the oncogenic fusion protein EWS::FLI1 is modulated by its DNA-binding domain (Libich & Bishop Labs)
- Nature Communications: Epigenetic silencing of DNA sensing pathway by FOXM1 blocks stress ligand-dependent antitumor immunity and immune memory. (Rao, Sung, & Chen Labs)
Events
Greehey CCRI Seminar Series – Fall ’25: Yatin M. Vyas, MBBS (Penn State Health)
Presentation Title: TBD
4th Annual Gear Up Against Kids Cancer Bike Ride
We’re excited to announce that the 4th Annual Gear Up Against Kids Cancer has been rescheduled for Saturday, October 18, 2025, at a new location: Floresville City Park (756 TX-97, Floresville, TX 78114), right next to the Event Center.